Valuation Tibet Rhodiola Pharmaceutical Holding Co.

Stocks

End-of-day quote Shanghai S.E. 04/09/2026			5-day change	1st Jan Change
38.06 ^CNY	+0.11%		-1.55%	-10.55%

08-13	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-01	Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025.	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Market Cap ¹	16,681	12,982	8,906	12,099	11,906	13,715
Change	-	-22.18%	-31.4%	35.86%	-1.59%	15.19%
Enterprise Value (EV) ¹	15,908	12,218	7,462	10,226	9,555	11,106
Change	-	-23.19%	-38.93%	37.05%	-6.56%	16.23%
P/E	39.8x	62.3x	24.1x	15.1x	11.3x	14.6x
PBR	6.48x	4.94x	2.96x	3.62x	3.04x	3.61x
PEG	-	-1.2x	0.3x	0x	0.4x	-1.4x
Capitalization / Revenue	12.1x	6.07x	3.49x	3.86x	4.24x	4.6x
EV / Revenue	11.6x	5.71x	2.92x	3.26x	3.4x	3.72x
EV / EBITDA	32.8x	18.7x	9.85x	9.25x	9.87x	11.1x
EV / EBIT	39.1x	21.3x	10.8x	9.85x	10.7x	12x
EV / FCF	207x	-208x	16.3x	17.5x	19.8x	15.9x
FCF Yield	0.48%	-0.48%	6.14%	5.73%	5.06%	6.28%
Dividend per Share ²	0.3923	0.26	0.5738	1.492	1.957	1.757
Rate of return	0.76%	0.65%	2.08%	3.97%	5.3%	4.13%
EPS ²	1.3	0.6462	1.146	2.485	3.26	2.91
Distribution rate	30.2%	40.2%	50.1%	60%	60%	60.4%
Net sales ¹	1,373	2,139	2,555	3,134	2,807	2,982
EBITDA ¹	485	654.2	757.5	1,105	967.6	1,002
EBIT ¹	407.3	572.7	688.3	1,039	893.4	924.7
Net income ¹	418.1	208.9	369.8	800.9	1,051	937.9
Net Debt ¹	-773.1	-763.6	-1,444	-1,873	-2,351	-2,609
Reference price ²	51.75	40.28	27.63	37.54	36.94	42.55
Nbr of stocks (in thousands)	322,319	322,319	322,319	322,319	322,319	322,319
Announcement Date	3/11/21 A	3/11/22 A	3/10/23 A	3/26/24 A	3/14/25 A	3/12/26 A

¹CNY in Million²CNY

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.	-	-	-	-	1.8B
ELI LILLY AND COMPANY	32.72x	11.9x	24.26x	0.6%	1,024B
JOHNSON & JOHNSON	30.62x	-	-	1.95%	663B
ABBVIE INC.	32.73x	7.6x	15.8x	2.67%	453B
ROCHE HOLDING AG	19.89x	4.73x	11.71x	2.8%	352B
NOVARTIS AG	22.72x	5.84x	14.51x	2.7%	304B
ASTRAZENECA PLC	20.87x	4.29x	12.24x	2.06%	252B
AMGEN INC.	27.66x	7.14x	13.15x	2.31%	236B
NOVO NORDISK A/S	13.33x	4.82x	10.06x	3.78%	206B
GILEAD SCIENCES, INC.	-46.14x	6.65x	25.95x	2.18%	187B
Average	17.16x	6.62x	15.96x	2.34%	368.02B
Weighted average by Cap.	24.05x	7.99x	17.80x	1.95%